JEFF EVANS

Cancer Research UK Scotland Institute — United Kingdom

Medicine · Health Sciences

11h-index4.8kcitations107works0.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cutaneous Melanoma Detection and Management(9), Bariatric Surgery and Outcomes(9), Hepatocellular Carcinoma Treatment and Prognosis(7), Immunotherapy and Immune Responses(7), Histone Deacetylase Inhibitors Research(6)

Publications104 total

Tolerability and Clinical Benefit Assessment of Continuous Roginolisib Administration in Patients with Cancer including Metastatic Uveal Melanoma
2025Open Access
Supplementary Table 3 from Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
2024Open Access
Supplementary Table 2 from Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
2024Open Access
Data from Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
2024Open Access
Supplementary Table 1 from Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
2024Open Access
131 Baseline and early follow-up radiomics biomarkers for tumor growth in uveal melanoma patients treated with roginolisib (IOA-244)
Regular and Young Investigator Award Abstracts·2024Open Access
Comparison between patient characteristics, aetiology and outcomes in patients with and without cirrhosis with hepatocellular carcinoma diagnosed in a regional centre
Frontline Gastroenterology·2024· 1 cited
Receptor tyrosine kinase co-amplification and benefit from HER2 inhibitors in biliary tract cancers
Journal of Hepatology·2022· 3 citedOpen Access
CTNI-49. PHASE 1 STUDY OF ST101, A FIRST-IN-CLASS PEPTIDE ANTAGONIST OF CCAAT/ENHANCER-BINDING PROTEIN ß, IN PATIENTS WITH ADVANCED SOLID TUMORS, WITH A PHASE 2 EXPANSION IN RECURRENT GLIOBLASTOMA MULTIFORME
Neuro-Oncology·2021
546 Results from Phase Ib study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)
Regular and Young Investigator Award Abstracts·2021· 4 citedOpen Access
Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
Clinical Cancer Research·2021· 85 citedOpen Access
Abstract CT214: ATRiUM: A first-in-human dose escalation phase I trial of ceralasertib (AZD6738) and gemcitabine as combination therapy
Cancer Research·2021· 2 cited
Abstract LB114: Tumor uptake and predictable PK of ST101 - a peptide antagonist of C/EBPβ - in patients with advanced unresectable and metastatic solid tumors
Cancer Research·2021
Effect of Hepatocellular Carcinoma Surveillance Programmes on Overall Survival in a Mixed Cirrhotic UK Population: A Prospective, Longitudinal Cohort Study
Journal of Clinical Medicine·2021· 20 citedOpen Access
Networks and Stakeholders: How are Networks created, and how do they evolve?
OSF Preprints (OSF Preprints)·2021Open Access
Schwachstellen beim Impfstofftransport
2021
382P The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: Final results from a phase I study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma (GBM)
Annals of Oncology·2020· 3 citedOpen Access
530MO Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ)
Annals of Oncology·2020· 1 cited
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
British Journal of Cancer·2020· 16 citedOpen Access
SUN-424 TREATMENT OF BRONCHIECTASIS WITH MACROLIDE IN ANCA-ASSOCIATED VASCULITIS ACHIEVED REMISSION: A CASE REPORT
Kidney International Reports·2020Open Access
page 1 of 6Next →

Frequent Co-authors

Pippa Corrie(8), Mark R. Middleton(7), Daniel H. Palmer(6), Ruth Plummer(6), Yuk Ting(5), Stephen Falk(4), Paul J. Ross(4), Jonathan Wadsley(4), Juan W. Valle(4), Bristi Basu(4), C Mulatero(4), Neil Steven(4), William Shingler(4), Yvonne McGrath(4), Bent K. Jakobsen(4), Harpreet Wasan(3), Lucy Wall(3), John P. Neoptolemos(3), Timothy Iveson(3), David Cunningham(3)